SCI-PUB

Myelodysplastic neoplasms

Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study.

Treosulfan has shown promise in allogeneic hematopoietic cell transplantation (HCT) for its myeloablative properties and low toxicity...

DOI: 10.1016/j.jtct.2024.04.014

Pasic I, Moya TA, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J

Transplantation and cellular therapy, 2024-04-24

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Assessment of individualized MRD using NGS + ddPCR is feasible and can be used for early detection of relapse. Positive MRD is associated with shorter RFS and OS (ClinicalTrials.gov identifier: NCT02872662).

DOI: 10.1200/JCO.23.01159

Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Olsnes Kittang A, Werlenius O, Lorentz F, Rasmussen B, Cammenga J, Weber D, Lindholm C, Wiggh J, Dimitriou M, Moen AE, Yip Lundström L, von Bahr L, Baltzer-Sol

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024-04-22

Наверх

Myelodysplastic neoplasms

Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study.

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Contact Us

Log In

Password recovery